Results 191 to 200 of about 3,784 (223)

Frequency and Implications of High-Risk Pharmacogenomic Phenotypes Identified in a Diverse Australian Pediatric Oncology Cohort. [PDF]

Clin Transl Sci
Moore C, Halman A, Stenta T, Khatri D, Williams E, Dyas R, Stolper J, Elliott DA, Conyers R.   +8 more
europepmc   +1 more source

Neuroimaging and Pathology Biomarkers in Parkinson's Disease and Parkinsonism. [PDF]

Brain Sci
Cilia R, Arnaldi D, Ballanger B, Ceravolo R, De Micco R, Del Sole A, Eleopra R, Endo H, Fasano A, Hoenig MC, Horsager J, Lehéricy S, Leta V, Moda F, Nolano M, Outeiro TF, Parkkinen L, Pavese N, Quattrone A, Ray NJ, Reich MM, Rektorová I, Strafella AP, Tagliavini F, Tessitore A, van Eimeren T.   +25 more
europepmc   +1 more source

New developments in imaging in ALS. [PDF]

J Neurol
Kleinerova J, Querin G, Pradat PF, Siah WF, Bede P.   +4 more
europepmc   +1 more source

Central cholinergic white matter pathways in prodromal and early manifest Lewy body disease

Eisenstein T, Groenewald K, van Hillegondsberg L, Al Hajraf F, Zerenner T, Lawton MA, Ben-Shlomo Y, Griffanti L, Hu MT, Klein JC.   +9 more
europepmc   +1 more source

Pharmacogenetic guided drug therapy – how to deal with phenoconversion in polypharmacy

Expert Opinion on Drug Metabolism & Toxicology
Introduction The prevalence of polypharmacy and the increasing availability of pharmacogenetic information in clinical practice have raised the prospect of data-driven clinical decision-making when addressing the issues of drug–drug interactions and ...
J. Stingl, Roberto Viviani
semanticscholar   +3 more sources

‘Phenoconversion’ in adult patients with β‐thalassemia

American Journal of Hematology
Rate and risk factors for phenoconversion from non-transfusion-dependent β-thalassemia (NTDT) to transfusion-dependent β-thalassemia (TDT) during a 10-year follow up of adult patients in Italy.
Khaled M. Musallam, Susanna Barella, R. Origa, G. B. Ferrero, Roberto Lisi, A. Pasanisi, Filomena Longo, Barbara Gianesin, G. Forni   +8 more
semanticscholar   +5 more sources

Clinical effects of CYP2D6 phenoconversion in patients with psychosis

Journal of Psychopharmacology
Background: Pharmacogenetics is considered a promising avenue for improving treatment outcomes, yet evidence arguing for the use of pharmacogenetics in the treatment of psychotic disorders is mixed and clinical usefulness is under debate.
E. D. De Brabander, Esmee M Breddels, Thérèse van Amelsvoort, R. van Westrhenen   +3 more
semanticscholar   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

CYP2D6 pharmacogenetics and phenoconversion in personalized medicine

Expert Opinion on Drug Metabolism & Toxicology, 2022
CYP2D6 contributes to the metabolism of approximately 20-25% of drugs. However, CYP2D6 is highly polymorphic and different alleles can lead to impacts ranging from null to increase in activity. Moreover, there are commonly used drugs that potently inhibit the CYP2D6, thus causing 'phenoconversion' which can convert the genotypic normal metabolizer into
Noor A, Nahid, Julie A, Johnson
openaire   +2 more sources

Phenocopy and Phenoconversion: Do they Complicate Association Studies?

Pharmacogenomics, 2012
Current pharmacogenetic focus on genotype A number of clinically relevant drug metabo­ lizing enzymes (DMEs) are expressed poly­ morphically in the population, giving rise to at least three distinct genotypes; extensive metabolizers (EMs), poor metabolizers (PMs) and intermediate metabolizers.
Rashmi R, Shah, Robert L, Smith
openaire   +2 more sources

The theoretical problems of “prodrome” and “phenoconversion” in neurodegeneration

2023
The recognition of and approach to prodromal symptoms, those which manifest before a diagnosis can be ascertained at the bedside, are of increasing interest in neurodegenerative research. A prodrome is conceived of as an early window into a disease, a critical time when putative disease-modifying interventions may be best suited for examination ...
Andrea, Sturchio, Alberto J, Espay
openaire   +2 more sources